GLP-1 receptor agonists, such as those approved for pediatric use (liraglutide and semaglutide), and/or other obesity pharmacotherapies, might offer a promising solution as an adjunct to surgery to mitigate these challenges [11–13]. Here, GLP1R is linked to obesity disorder.